Dividends Inside Welcome to Dividends Inside
Welcome to Dividends Inside!
The platform is currently in beta, so some features and data may still change as we improve the service. If you have questions, feedback, or run into anything unexpected, please contact us at info@dividendsinside.com.
Welcome to Dividends Inside!
The platform is currently in beta, so some features and data may still change as we improve the service. If you have questions, feedback, or run into anything unexpected, please contact us at info@dividendsinside.com.
Avenue Therapeutics Inc
ATXI
$0.28 (- $0.03 - 9.62%)
Last updated: 2026-05-20 15:49 UTC
About the Company
Avenue Therapeutics is a specialty pharmaceutical company focused on developing and commercializing therapies for treating neurologic diseases. The company is headquartered in Bay Harbor Islands, Florida and operates as a subsidiary of Fortress Biotech. Avenue Therapeutics pursues a focused pipeline of product candidates designed to address serious neurological conditions. These include AJ201, currently in clinical development for spinal and bulbar muscular atrophy, intravenous tramadol for post-operative acute pain management as a potential alternative to conventional opioids in intensive care settings, and BAER-101 for epilepsy and panic disorders. The company's strategy centers on acquiring, licensing, and commercializing pharmaceutical products tailored for hospital intensive care environments. By focusing on underserved neurological and rare disease indications, Avenue Therapeutics aims to provide therapeutic options that address unmet medical needs in specialized treatment settings.
Price History
Latest News for ATXI
Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease
ATX-04 is a selective β2-adrenergic agonist with human proof-of-concept data demonstrating improved muscle function and enhanced response to enzyme replacement therapy MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (OTC: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for rare and neurologic diseases, today announced that it has entered into an exclusive worldwide license agreement with Duke U
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy
Axsome obtains exclusive global rights to AZD7325, a novel oral selective GABAA α2,3 receptor positive allosteric modulator Deepens Axsome’s broad and innovative neuroscience portfolio with a synergistic early-stage program for epilepsy NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into an agreement to obtain exclusi
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics
Baergic shareholders eligible to receive up to approximately $82 million in potential development, regulatory, and sales milestones plus a tiered mid-to-high single digit royalty on global net sales from AxsomeMIAMI, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (OTC: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, and its majority-owned subsidiary, Baergic
Delisting of Securities from The Nasdaq Stock Market
NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock and warrants of NKGen Biotech, Inc. NKGen Biotech, Inc.’s securities were suspended on March 5, 2025 and have not traded on Nasdaq since that time. Nasdaq also announced today that it will delist the common stock, rights, and units of Aquaron Acquisition Corp. Aquaron Acquisition Corp.’s securities were suspended on March 7, 2025 and have not traded on Nasdaq since that time.